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Abstract
Background: One third of older people are estimated to die with dementia, which is a principal cause of death in
developed countries. While it is assumed that people die with severe dementia this is not based on evidence.
Methods: Cohort study using a large secondary mental healthcare database in North London, UK. We included
people aged over 65 years, diagnosed with dementia between 2008 and 2016, who subsequently died. We
estimated dementia severity using mini-mental state examination (MMSE) scores, adjusting for the time between
last score and death using the average annual MMSE decline in the cohort (1.5 points/year). We explored the
association of sociodemographic and clinical factors, including medication use, with estimated MMSE score at
death using linear regression.
Results: In 1400 people dying with dementia, mean estimated MMSE at death was 15.3 (standard deviation 7.0). Of
the cohort, 22.2% (95% confidence interval 20.1, 24.5) died with mild dementia; 50.4% (47.8, 53.0) moderate; and 27.
4% (25.1, 29.8) with severe dementia.
In fully adjusted models, more severe dementia at death was observed in women, Black, Asian and other ethnic
minorities, agitated individuals, and those taking antipsychotic medication.
Conclusions: Only one quarter of people who die with dementia are at the severe stage of the illness. This finding
informs clinical and public understanding of dementia prognosis. Provision of end-of-life services should account
for this and healthcare professionals should be aware of high rates of mild and moderate dementia at end of life
and consider how this affects clinical decision-making.
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Background
Dementia is a principal cause of death in England and
Wales [1] and the United States [2], and it is estimated
that a third of people over the age of 60 die with the con-
dition [3]. Estimates of survival after disease onset have
varied between 3.3 and 11.7 years [4] – and the uncer-
tainty over prognosis creates difficulties for patients and
their family carers about planning their life and how to
prepare for end of life care [5]. The variability in survival
time in dementia is most likely a consequence of other ill-
nesses affecting survival. Some studies report a trend in
recent years towards compression of morbidity, where the
onset of the first chronic illness occurs at a later age, thus
compressing the time living with chronic illnesses [6].
There is increasing emphasis on providing good end
of life care in dementia, which tends to focus on the
challenges of delivering it to people with severe demen-
tia [7]. The proportion of people who have mild, moder-
ate, and severe dementia at end of life has important
implications for clinician- and public-awareness of prog-
nosis, how healthcare services plan and implement treat-
ment, and how clinicians provide evidence-based end of
life care. Severe dementia is associated with lack of
insight and capacity [8] to make decisions about health-
care, requiring others to make decisions on behalf of pa-
tients [9]. Someone with mild dementia is more likely to
be able to make these decisions, but may require support
to do so and to implement them. If many people who
have dementia die with a mild form of the condition,
this would have implications for palliative settings and
may suggest a greater need for support for decision
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making and management strategies. One study reported
that 31/68 (46%) people with dementia being managed
at end of life by a general practitioner were described by
the clinician as having mild dementia, [10] however
there has been, to our knowledge, no study examining
the distribution of dementia severity in a large cohort of
people with dementia at time of death.
In this study, we therefore aim to investigate the sever-
ity of dementia at death, in a secondary mental health-
care service cohort of older people with a diagnosis of
dementia and explore the association between demo-
graphic and clinical factors, including medication use
(antidepressant, sedative and antipsychotic drugs, and
those for cognition in dementia), and dementia severity
at death.
Methods
Study setting and data source
We conducted a retrospective cohort study using rou-
tinely collected data from clinical dementia services in
Camden and Islington NHS Foundation Trust (CIFT), a
large mental health trust providing mental healthcare
services including dementia assessment and treatment to
a catchment area of 470,000 people in two London bor-
oughs. We obtained our data using the Clinical Record
Interactive Search (CRIS) system, a platform designed to
facilitate the use of routinely collected electronic health
records for research, which has been used to address a
number of research hypotheses in mental health and de-
mentia research [11]. CRIS allows the extraction of data
from electronic health records’ structured and unstruc-
tured (e.g. progress notes, clinic letters) fields using the
General Architecture for Text Engineering (GATE) pro-
gram, which uses natural language processing (NLP) al-
gorithms [12], to identify text relating to diagnosis,
treatment or other clinical information. The Camden
and Islington CRIS database holds pseudo-anonymised
electronic mental health records dating from 1st January
2008 for over 116,000 people who have had contact with
CIFT services [13]. Individual patient consent is not re-
quired for inclusion in the database.
Study patients
We retrieved records from eligible patients who had
clinical contact with CIFT services during the study win-
dow (1st January 2008 to 30th September 2016).
Individuals were included if they:
 were aged 65 years or over at dementia diagnosis,
ascertained either using a structured field diagnosis
of International Classification of Diseases (ICD) 10
codes F00–03 [14], or an unstructured diagnosis
(derived though NLP application)
 had their cognitive function assessed and recorded using
the Mini-Mental State Examination (MMSE) [15]
 died before 30th September 2016
We excluded patients who received a diagnosis of Mild
Cognitive Impairment (MCI) after dementia diagnosis
(n = 15); this was judged to be an active clinical decision
to replace dementia diagnosis with MCI, as it is not pos-
sible to have MCI and dementia simultaneously.
Study data
Outcome
Dementia severity at death was assessed using the last
recorded MMSE score before death. The MMSE scale is
commonly used by healthcare professionals to assess
cognitive impairment and monitor progression of de-
cline in people with dementia. It is scored out of 30, and
has been found to have acceptable psychometric proper-
ties to rate dementia severity [16]. We extracted all re-
corded MMSE scores from the unstructured fields of
patient records, using the NLP application. Each MMSE
score was accompanied by a post processing rule (PPR)
code which provided information about the quality of
the score recording and extraction [17]. A PPR code of 0
indicates that the MMSE has been optimally recorded
and codes from 1 to 12 indicated a range of possible
problems, such as that the numerator was higher than
the denominator, or that more than one record with dif-
ferent scores were recorded on the same date. For all eli-
gible patients, we used the PPR codes to select the valid
MMSE records.
We validated the application for extracting and coding
MMSE score. We calculated the positive predictive value
(PPV) by randomly selecting MMSE scores and dates
(n = 100) and determining if these were accurate by
manually searching through the source documents in
which they had been recorded. To obtain sensitivity, we
extracted and read through a random set of documents
(n = 100) which contained the word ‘MMSE’ to ascertain
whether there was mention of MMSE score, then deter-
mining if this agreed with the coding performed by the
NLP. The PPV for MMSE scores was 98%, though the
accuracy of dates was substantially lower (67% overall)
due to a technical problem which meant that a large
proportion were marked with the date of migration to a
new electronic clinical record system; so we manually
corrected these dates. The sensitivity of the MMSE ap-
plication was 94%.
Covariates
We obtained information on age at diagnosis, sex, ethni-
city (White, Black, Asian, and other), marital status and
the last recorded dementia subtype (categorised into 5
groups; Alzheimer’s disease, vascular dementia, dementia
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with Lewy bodies, other, and unspecified). We estimated
socio-economic status using the area-level of socio-eco-
nomic deprivation by matching lower super output area
(LSOA) score to the 2010 Index of Multiple Deprivation
(IMD) [18]. We obtained information on clinical presenta-
tion using patient’s Health of The Nations Outcome Scales
(HoNOS) score within a year of diagnosis. HoNOS is a 12
subscale assessment tool with acceptable psychometric
properties [19] which is routinely administered at 6
monthly intervals after initial assessment. We used the do-
mains covering the neuropsychiatric symptoms of clinical
interest- agitation, hallucination and depressed mood. Be-
cause only scores ≥2 are considered clinically significant,
we categorised each domain as binary, with 0–1 cate-
gorised as ‘no problem’ and 2–4 as evidence of ‘problem’.
Data on recorded medication use (derived from a GATE
text extraction) [20] any time after dementia diagnosis, in-
cluding drugs for cognition (acetyl-cholinesterase inhibi-
tors and memantine), antipsychotics, antidepressants and
sedatives (benzodiazepine or ‘z-drug’ hypnotics), were also
extracted using NLP application.
Statistical analysis
We first described the sociodemographic and clinical
characteristics of our sample.
Estimating dementia severity at death
We assumed that cognition would decline during the
time between the last MMSE assessment and death. We
therefore estimated MMSE at death by calculating the
mean annual MMSE decline using individuals’ last two
MMSE scores and, for each patient, multiplying the dur-
ation between their last MMSE and death by the co-
hort’s annual MMSE decline. We report this, as well as
the distribution of dementia severity at death, rating
MMSE ≥20 points as mild dementia, < 20 and ≥ 10 as
moderate, and < 10 as severe dementia, with 95% confi-
dence intervals for these proportions. As we judged that
variable interval between last recorded MMSE and death
might reduce the accuracy of our adjustment procedure,
we conducted a sensitivity analysis using a subgroup of
patients who had been assessed close to death (last re-
corded MMSE score within one year of their death),
with the same adjustment procedure.
Exploring predictors of dementia severity at death
We examined associations between estimated MMSE
scores (continuous outcome variable) and each covariate
(predictor variables), using linear regression. We first
conducted univariable analyses of the association be-
tween each covariate and severity of dementia at death
and then our planned primary mutually-adjusted multi-
variable analysis of the association between these factors
and dementia severity at death. Due to a large amount
of missing data, with slight differences in sex, ethnicity
and socio-economic status between those with complete
data and those with missing data, we also conducted an
analysis without the HoNOS variables. We also con-
ducted a sensitivity analysis using the same regression
analysis on the subgroup whose last MMSE was within a
year of their death. In all multivariable analyses, we ad-
justed for time between diagnosis and death as we con-
sidered that this would be a strong confounding factor.
Exploring the influence of medication use after dementia
diagnosis on dementia severity at death
We conducted univariate and multivariable analyses for
associations between our outcome and use of drugs for
cognition, antipsychotics, antidepressants and sedatives
after dementia diagnosis, adjusting for all the covariates
and each medication individually.
All data analysis was completed using STATA (version 11).
Ethics approval and access to the data
Ethical approval for the analysis of the CIFT CRIS data-
base was obtained from the National Research Ethics
Service Committee East of England—Cambridge Central
(14/EE/0177).
Results
The clinical and demographic characteristics of the co-
hort are displayed in Table 1. Our final cohort consisted
of 1400 people. The median age at diagnosis was
84.6 years, and the mean time between diagnosis and
death was 1.9 years (standard deviation (s.d.) = 1.7) and
maximum time from diagnosis to death was 11.9 years.
For those who died with mild dementia, mean time be-
tween diagnosis and death was 1.6 (1.4) years; for mod-
erate dementia 1.9 (1.7) and for severe dementia 2.2
(1.9). The majority of individuals were White, and Black
people formed the largest minority group. Of those with
a recorded diagnosis, Alzheimer’s disease was the most
common subtype, followed by vascular dementia. Mean
MMSE closest to time of diagnosis was 18.2 (6.6).
Around one quarter of patients had clinically significant
agitation at diagnosis and one fifth had depressive symp-
toms. Just under half were recorded as taking medica-
tion for cognition in dementia after their diagnosis and
30% took antidepressants.
Severity of dementia at death
The mean last MMSE score was 17.0. The mean annual
MMSE decline between penultimate and last MMSE as-
sessment was 1.5 points and the mean time from last
MMSE score to death was 1.4 years (s.d. = 1.64). The
mean estimated MMSE score at death was 15.3 (s.d. =
7.0) (Table 2). We found that 27.4% (95% confidence
interval 25.1, 29.8) had severe dementia, 50.4% (47.8,
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53.0) had moderate dementia at death, and 22.2% (20.1,
24.5) died with mild dementia (Table 2). The estimated
MMSE scores at death were normally distributed except
that 46 people had a floor MMSE score estimated as
0 (Fig. 1).
In our sensitivity analysis, which included only the 782
people who had their last MMSE within one year of
death (Table 2), we found a similar proportion of people
had moderate dementia but that a higher proportion
(32.1%) had severe dementia at death. The mean MMSE
was however, slightly higher (16.3 (s.d. = 6.8)).
Clinical and demographic predictors of dementia severity
at death
In the fully adjusted linear regression model (Table 3),
we included 452 people with all the covariates recorded.
This showed that women, those of minority ethnicity
background, those from more socio-economically de-
prived backgrounds, and those with agitation died with
more severe dementia. Women were estimated to score
1.4 MMSE points lower at death (0.1, 2.8, p = 0.04).
Similarly, those from a Black, Asian and other ethnic
origin scored 3.5 (1.5, 5.5, p = 0.001) points, 4.7 (0.5, 9.0,
p = 0.03) and 5.2 (0.8, 9.7, p = 0.02) points lower respect-
ively on the estimated MMSE, compared to White
people. Worse score on the IMD was associated with
dying with more severe dementia, with each 10 point in-
crease in deprivation score associated with 0.4 points
lower on the MMSE (0.0, 0.8, p = 0.04). Having problems
with agitation was associated with estimated MMSE 2.5
points (1.0, 4.0, p = 0.001) lower. Conversely, those who
were divorced scored 2.2 points (0.0, 4.3, p = 0.05)
higher on the MMSE. In the regression analysis without
the HoNOS variables, which included 1131 people, the
results were similar to that of our primary analysis, with
the exception that those who were single died with less
severe dementia (1.3 points higher on the MMSE (0.1,
2.5, p = 0.03) and no association for ‘other’ ethnic origin
with dementia severity at death was found. In our sensi-
tivity analysis assessing factors associated with estimated
MMSE in the 291 people who had been assessed within
one year of death and had complete covariate data (Add-
itional file 1), similar results were obtained, except that
ethnicity was no longer associated with dementia sever-
ity at death.
Association between use of medication and dementia
severity at death
Multivariable analysis of the association between differ-
ent medication use after dementia diagnosis and severity
of dementia at death (Table 4), showed that use of anti-
psychotics was associated with scoring 2.7 points lower
on the MMSE at death than individuals who had not
taken antipsychotics (0.9, 4.6, p = 0.004). Use of other
Table 1 Clinical and demographic characteristics of patients
(n = 1400)
Characteristic All people with
dementia
n (%)










Sex Female 758 (54.1)










Last recorded dementia type Alzheimer’s disease 645 (46.1)






IMD Mean (SD) 31.0 (12.6)
Missing 115




Depressed mood 123 (21.0)
Missing** 810
Any recorded use of medication,
after diagnosis of dementia




MMSE score at diagnosis Mean (SD) 18.2 (6.6)
Time between diagnosis and
death – (years)
Mean (SD) 1.9 (1.7)
KEY: SD = standard deviation; IQR = interquartile range; IMD = Index of Multiple
Deprivation; HoNOS = Health of the Nation Outcome Scales; MMSE =Mini-
mental state examination
Notes: *HoNOS categories dichotomised to 0–1 (no or minor problem) and 2–
4 (problem behaviour)); ** The number of missing data varies according to
HoNOS items (between 808 and 810)
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psychotropic medication was not associated with de-
mentia severity at death.
Discussion
This is the first study, to our knowledge to report the se-
verity of dementia at death of a cohort of people with
dementia. Importantly we find that only one quarter had
severe dementia, half had moderate dementia and the
rest had mild dementia at death. The mean MMSE at
death was 15.3 and we found a normal distribution of
estimated MMSE scores at death except for those with
estimated MMSE score of 0, a consequence of the floor
effect of the MMSE assessment.
This result was unexpected as we had anticipated that
most people in the cohort would die with severe demen-
tia. It suggests that most of our cohort died from other
illnesses rather than solely from the consequences of ad-
vanced dementia, although the presence of dementia
may have led to a worse prognosis than others with the
same illness [21]. The age-specific incidence of dementia
has decreased in the UK over the past 20 years [22],
meaning that the condition occurs later now than in
previous generations, and is therefore more likely to
coexist with other illnesses. Around 70% of people with
dementia have at least two comorbid chronic diseases
and these increase the risk of hospitalisation and mortal-
ity [23]. This elevated mortality may have contributed to
a large proportion of our cohort dying with milder forms
of the disease. Furthermore, a major drive in dementia
policy in the UK and other countries has been early
diagnosis of dementia [24] and the services whose data
we used have been successful at increasing dementia
diagnosis [25], so our naturalistic cohort includes many
who had dementia diagnosed at very mild stages, who
may have died from other conditions, with less severe
dementia.
The mean MMSE was slightly lower in the whole sam-
ple than in our sensitivity sub-group of people assessed
within one year of their death, as the whole cohort in-
cluded a higher number of people (46 v 24 people)
whose estimated MMSE was 0, due to a long interval be-
tween their last MMSE and death. In the sensitivity ana-
lysis, a higher proportion of people had severe dementia
than in the main analysis, which may be because our
method underestimated the decline, which may be more
precipitous before death, or because people with more
Fig. 1 Distribution of mini-mental state examination (MMSE) scores at death (n = 1400)
Table 2 Distribution of dementia severity at death, using estimated mini-mental state examination scores
Estimated MMSE scores
(n = 1400)
Estimated MMSE scores within
1 year of death (n = 782)
Mean (SD) 15.3 (7.0) 16.3 (6.8)
Dementia severity
n (% (95% CI))
Mild 311 (22.2 (20.1, 24.5)) 142 (18.2 (15.6, 21.0))
Moderate 706 (50.4 (47.8, 53.0)) 389 (49.7 (46.3, 53.2))
Severe 383 (27.4 (25.1, 29.8)) 251 (32.1 (28.9, 35.5))
KEY: MMSE =mini-mental state examination
Notes: Mild dementia = estimated MMSE 20–30; moderate dementia = 10–19; Severe dementia = 0–9
Aworinde et al. BMC Psychiatry          (2018) 18:355 Page 5 of 9
advanced dementia were more likely to have been seen
and cognitively assessed by the clinical service close to
death.
More severe dementia at death was associated with be-
ing female, from ethnic minority background, more so-
cioeconomically deprived, showing symptoms of
agitation and taking antipsychotic medication. Divorced
people died with less severe dementia. Our observational
analyses of the association between sociodemographic
and clinical factors and dementia severity cannot estab-
lish a causal relationship. The identified factors may
cause dementia to progress more rapidly; they may indi-
cate people with lower cognitive reserve [26] and there-
fore more severe cognitive impairment at the same
pathological stage of the disease; or they may indicate
those with better physical health who therefore live lon-
ger with dementia and have the condition more severely
when they die.
Table 3 Association between clinical and demographic characteristics and mini-mental state examination scores at death
Characteristic Univariable analysis Multivariable analysis (n = 452)
Coefficient 95% CI P-value Coefficient 95% CI P-value
Age at diagnosis (per 1 year increase) 0.0 −0.0 to 0.1 0.20 −0.0 − 0.1 to 0.1 0.75
Sex Reference category:
Male




Black −3.4 −4.8 to − 2.0 0.001 − 3.5 −5.5 to − 1.5 0.001
Asian − 2.7 − 4.9 to −0.5 0.02 − 4.7 −9.0 to − 0.5 0.03
Other −0.3 −2.6 to 2.0 0.80 −5.2 −9.7 to − 0.8 0.02
Marital status Reference category:
Married
0.001* 0.26*
Widowed 0.7 −0.3 to 1.7 0.18 0.8 −0.9 to 2.4 0.36
Divorced 1.3 −0.1 to 2.7 0.07 2.2 0.0 to 4.3 0.047
Single 1.8 0.7 to 2.9 0.002 0.7 −1.1 to 2.5 0.45
Dementia type Reference category:
Alzheimer’s disease
0.004* 0.43*
Vascular dementia −0.2 −1.2 to 0.8 0.71 −1.1 −2.9 to 0.9 0.28
Dementia with Lewy bodies 0.5 −1.9 to 3.0 0.68 1.8 −3.0 to 6.6 0.46
Other 1.8 0.5 to 3.0 0.008 1.0 −1.0 to 3.0 0.33
Unspecified 1.4 0.4 to 2.3 0.004 0.3 −1.2 to 1.9 0.69
IMD (per 10-unit increase in deprivation) −0.3 −0.5 to −0.0 0.04 − 0.4 −0.8 to − 0.0 0.04
HoNOS at diagnosis – problems with**: Agitation −2.3 −3.6 to −1.1 0.001 −2.5 −4.0 to −1.0 0.001
Hallucinations −1.8 −3.3 to −0.4 0.02 −0.7 −2.4 to 1.0 0.43
Depressed mood −0.3 −1.6 to 1.1 0.70 0.7 −0.8 to 2.3 0.37
Time between diagnosis and death (per 1 year later) −0.7 −0.9 to − 0.5 0.001 −0.5 −1.1 to 0.0 0.06
KEY: IMD = Index of Multiple deprivation; HoNOS = Health of the Nation Outcome Scales; clinical symptoms were derived from HoNOS scale
Notes: * overall class effect for categorical variables; ** HoNOS categories dichotomised to 0–1 (no or minor problem) and 2–4 (problem behaviour))
Table 4 Association between medication use and mini-mental state examination score at death
Any recorded use of
medication after dementia
diagnosis
Univariable analysis Multivariable analysis a (n = 452)
Coefficient 95% CI P-value Coefficient 95% CI P-value
Acetylcholinesterase inhibitors /
memantine
−0.6 − 1.3 to 0.2 0.12 − 0.0 − 1.6 to 1.6 0.97
Antidepressants 0.2 −0.7 to 0.9 0.72 0.1 −1.4 to 1.6 0.94
Sedatives −1.6 −2.5 to −0.7 0.001 −1.1 − 2.8 to 0.7 0.24
Antipsychotics −2.7 −3.6 to −1.8 < 0.001 − 2.7 −4.6 to −0.9 0.004
Notes: a adjusted for age, sex, ethnicity, marital status, IMD, dementia type, problems with agitation, hallucinations and depression (from HoNOS scale) and time
between diagnosis and death
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We found that women died with more severe dementia
than men, which may result from this cohort of women
having received less education [27] and therefore having
less cognitive reserve so showing more severe cognitive
symptoms for the same level of pathology, or be a conse-
quence of their greater life-expectancy, allowing more de-
mentia progression before death. Our finding that people
from minority ethnic background died with more severe
dementia than their white counterparts may also reflect
lower cognitive reserve related to less education [28]. In
addition, people from ethnic minority backgrounds de-
velop dementia at a younger age [29] and may therefore
live longer with the disease. A final explanation is that
people from minority groups present later [30], so those
who die with less severe illness may never have presented
to memory services. Alternatively, people from ethnic mi-
nority origins may engage less with management of their
condition [31], thus experience a more precipitous cogni-
tive decline. Higher neighbourhood level socioeconomic
deprivation being associated with more severe dementia at
death is also likely to result from lower cognitive reserve
and younger development of dementia [32]. Our finding
that divorced individuals died with less severe dementia
compared to married people may be due to the mortality
risks associated with being divorced [33] meaning di-
vorced individuals died earlier and with milder dementia
than married people.
Our results showed agitation to be associated with
more severe dementia at death and this is likely to be
because agitation at diagnosis is a consequence of more
severe dementia, which increases in severity as dementia
progresses [34]. An alternative is that agitation caused
more rapid dementia progression, supported by studies
suggesting that neuropsychiatric symptoms increase
neuropathological burden [35]. Antipsychotics are used
for psychosis or sometimes agitation, which are markers
of more severe dementia, although the potential contri-
bution of antipsychotic use to cognitive decline [36]
needs further exploration.
Strengths and limitations
This is the first study, to our knowledge, to evaluate de-
mentia severity at death and examine demographic and
clinical predictors. Our database allowed analysis of all
routinely collected clinical data, with no requirement for
explicit consent to involvement in the database, meaning
that we had a large naturalistic cohort of people who
had been clinically-diagnosed with dementia before
dying. Our results are likely to be representative of
people with clinically-diagnosed dementia living in simi-
lar areas, as memory services are the mainstay of UK de-
mentia diagnosis and assessment [24] and CIFT has a
high estimated diagnosis rate – 84% of people in the
catchment area estimated to have dementia from
epidemiological studies, have a formal diagnosis [25] –
but our findings may not generalise to people with de-
mentia who have not been diagnosed, who may have
been more likely to die with milder dementia.
Our study has limitations; the use of electronic health
records which were not collected for research purposes
meant that we could only adjust for routinely recorded
factors. We would have liked to adjust for education,
which would be a more sensitive marker of cognitive re-
serve than socioeconomic deprivation, and would have
ideally had more sensitive measures of physical-ill
health, enabling us to examine in detail the potential
confounding effect of physical illness on dementia sever-
ity at death. Our analysis assumed a linear decline in
MMSE at end of life, and applied the average MMSE de-
cline to the whole sample, whereas this may not be the
case. Rate of decline likely depends on a number of fac-
tors including initial severity, type of dementia, age,
neuropsychiatric symptoms, medication, sex and educa-
tion and we did not have data on all these domains to
allow us to predict decline for each patient individually,
so we used the mean rate of decline in the sample. The
mean annual rate of decline in our sample was 1.5
MMSE points. One study reported 6 month MMSE de-
cline of 0.9 points [37], whilst others have reported an
annual decline of 2.2–2.3 points [38, 39], although these
studies only examined people with Alzheimer’s disease,
whereas we included people with all dementia types and
the rate of decline differs according to dementia type
[40]. Finally, for some patients, it is possible that MMSE
testing was abandoned when they had more severe de-
mentia as the patient may struggle to complete testing
and/or the clinician may deem that it does not add sig-
nificant information, although clinicians would often
record the MMSE score at the point of abandoning the
test; however, reduced recording of MMSE in severe de-
mentia may mean that dementia severity is underesti-
mated in this study.
Conclusions
We found the majority of people in the sample died with
moderate dementia and only one quarter had severe de-
mentia at death. This study provides important informa-
tion for clinicians and the public about the prognosis of
people with dementia and should inform the develop-
ment of end-of-life services tailored to the condition.
Dying with severe dementia is a major concern for
people with early disease [41], but we found that this oc-
curs less frequently than expected. People with demen-
tia, their family carers, and healthcare professionals
involved in their care may delay decisions related to
end-of-life, assuming this may not be relevant, and re-
search suggests that take-up of advance care plans has
been low; [42] however, our research supports the need
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for professionals to encourage early discussions about
who may help with decisions and end-of-life preferences.
All palliative care in older people should consider if the
individual has dementia and how this affects their
decision-making ability, the possible treatments and
their ability to carry out a plan without help. People with
mild to moderate dementia often appear unimpaired in
social contexts to people who do not know them and it
is easy to miss the disability that their cognitive impair-
ment may cause. Clinicians involved in end of life care
should consider the presence of dementia in people with
less obvious signs of the condition and take this into ac-
count when explaining clinical information and making
treatment decisions.
Additional file
Additional file 1: Appendix 1. Association between clinical and
demographic characteristics and the mini-mental state examination at
death, using only scores recorded within one year of death. Appendix 2.
Flow diagram of study patient inclusion/exclusion. (DOCX 41 kb)
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